{
  "id": "mhgap#risk_safety_dc54f179",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders 3.8 Epilepsy and seizures (EPI) EPI1. In adults with established status epilepticus, i.e. seizures persisting after the first-line agent (benzodiazepine-resistant status epilepticus), which antiseizure medicines are associated with better clinical outcomes (stopping seizures and with less adverse effects)? Recommendation (update): In adults with established status epilepticus, i.e. seizures persisting after two doses of benzodiazepines, either intravenous fosphenytoin, intravenous phenytoin, intravenous levetiracetam, intravenous phenobarbital or intravenous valproic acid (sodium valproate) should be considered with appropriate monitoring. The choice of these medicines depends on local resources, including availability and facilities for monitoring. Strength of recommendation: Conditional Certainty of evidence: Low Justification y There is insufficient evidence to recommend y A new systematic review was conducted: Sharma et lacosamide and diazepam infusion at this time. al., 2023 (8 RCTs).12 Remarks y There is low- to moderate-quality evidence that y Status epilepticus is a medical emergency which can there is no clinically important difference in efficacy lead to profound systemic and neurological damage between intravenous fosphenytoin, levetiracetam, and is associated with significant short-term and phenytoin or sodium valproate for the treatment long-term mortality. Timely control of status of benzodiazepine-resistant status epilepticus epilepticus is of paramount importance to improve in adults. There is low-quality evidence that the outcomes. phenobarbital may be more effective than sodium y A staged treatment protocol for management of valproate in the treatment of benzodiazepine- status epilepticus is recommended. resistant status epilepticus in adults. y There is low- to moderate-quality evidence that – Approximately 30–40% of all individuals fail to respond to initial treatment with benzodiazepines the safety profile of levetiracetam was better than (benzodiazepine-resistant or established status fosphenytoin, in terms of lesser cardiovascular epilepticus) and need further treatment with adverse events. There is low-quality evidence other intravenous antiseizure medicines (ASMs). that phenobarbital has a higher risk of respiratory The treatment of established status epilepticus is depression and cardiovascular adverse effects as the focus of this recommendation with the above compared with sodium valproate. medicines initiated when seizures persist after y Another factor of concern is the speed of two doses of benzodiazepines. administration. Fosphenytoin, levetiracetam and y Advantages of levetiracetam and sodium valproate sodium valproate can be administered within 10 include lesser risk of adverse effects as compared minutes, whereas phenobarbital and phenytoin with fosphenytoin. Both levetiracetam and sodium need to be infused over 20 minutes. Time is of the valproate are broad spectrum medicines active essence while treating status epilepticus. 12 Sharma S, Jain P, Aneja S. Antiseizure medicine treatment for established status epilepticus in adults. 2023 (in preparation). 76 3. Recommendations against all types of seizures, and hence may be a Research gaps good agent for maintenance therapy after the acute y Most of the evidence is from HICs. Further research is",
  "gloss_vi": "Mental health gap action programme (mhgap) guideline for mental, neurological and substance use disorders 3.8 epilepsy and seizures (epi) epi1. in adults with established status epilepticus, i.e.",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "management"
    ],
    "life_topics": [
      "study"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders 3.8 Epilepsy and seizures (EPI) EPI1. In adults with established status epilepticus, i.e. seizures persisting after the first-line agent (benzodiazepine-resistant status epilepticus), which antiseizure medicines are associated with better clinical outcomes (stopping seizures and with less adverse effects)? Recommendation (update): In adults with established status epilepticus, i.e. seizures persisting after two doses of benzodiazepines, either intravenous fosphenytoin, intravenous phenytoin, intravenous levetiracetam, intravenous phenobarbital or intravenous valproic acid (sodium valproate) should be considered with appropriate monitoring. The choice of these medicines depends on local resources, including availability and facilities for monitoring. Strength of recommendation: Conditional Certainty of evidence: Low Justification y There is insufficient evidence to recommend y A new systematic review was conducted: Sharma et lacosamide and diazepam infusion at this time. al., 2023 (8 RCTs).12 Remarks y There is low- to moderate-quality evidence that y Status epilepticus is a medical emergency which can there is no clinically important difference in efficacy lead to profound systemic and neurological damage between intravenous fosphenytoin, levetiracetam, and is associated with significant short-term and phenytoin or sodium valproate for the treatment long-term mortality. Timely control of status of benzodiazepine-resistant status epilepticus epilepticus is of paramount importance to improve in adults. There is low-quality evidence that the outcomes. phenobarbital may be more effective than sodium y A staged treatment protocol for management of valproate in the treatment of benzodiazepine- status epilepticus is recommended. resistant status epilepticus in adults. y There is low- to moderate-quality evidence that – Approximately 30–40% of all individuals fail to respond to initial treatment with benzodiazepines the safety profile of levetiracetam was better than (benzodiazepine-resistant or established status fosphenytoin, in terms of lesser cardiovascular epilepticus) and need further treatment with adverse events. There is low-quality evidence other intravenous antiseizure medicines (ASMs). that phenobarbital has a higher risk of respiratory The treatment of established status epilepticus is depression and cardiovascular adverse effects as the focus of this recommendation with the above compared with sodium valproate. medicines initiated when seizures persist after y Another factor of concern is the speed of two doses of benzodiazepines. administration. Fosphenytoin, levetiracetam and y Advantages of levetiracetam and sodium valproate sodium valproate can be administered within 10 include lesser risk of adverse effects as compared minutes, whereas phenobarbital and phenytoin with fosphenytoin. Both levetiracetam and sodium need to be infused over 20 minutes. Time is of the valproate are broad spectrum medicines active essence while treating status epilepticus. 12 Sharma S, Jain P, Aneja S. Antiseizure medicine treatment for established status epilepticus in adults. 2023 (in preparation). 76 3. Recommendations against all types of seizures, and hence may be a Research gaps good agent for maintenance therapy after the acute y Most of the evidence is from HICs. Further research is Mental health gap action programme (mhgap) guideline for mental, neurological and substance use disorders 3.8 epilepsy and seizures (epi) epi1. in adults with established status epilepticus, i.e."
}